Results 271 to 280 of about 31,041 (297)

Antiplatelet activity of tetramethylpyrazine

Thrombosis Research, 1994
Tetramethylpyrazine (TMPZ) is an active ingredient of a Chinese herbal medicine. We have previously shown that TMPZ possesses antithrombotic activity in rat thrombotic models. Inhibition of platelet aggregation and promotion of disaggregation contributed to the antithrombotic activity of TMPZ.
Diane M. Sylvester, Si-Yu Liu
openaire   +2 more sources

Advances in antiplatelet therapy

Expert Opinion on Emerging Drugs, 2003
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality in the western world. These disorders share a common pathophysiology -- atherosclerosis, which affects various arterial beds, leading to protean manifestations (coronary artery disease [CAD], stroke, peripheral arterial disease [PAD]).
Deepak L. Bhatt, Hani Jneid
openaire   +3 more sources

Aspirin as an Antiplatelet Agent

Archives of Internal Medicine, 1980
To the Editor. —There have been many studies relating the effect of aspirin prophylaxis on thromboembolisms. 1,2 Evaluation of the clinical data presented in them indicates that thromboembolic disease developed more rarely in men than in women under the identical dosage of aspirin given for prophylaxis against thromboembolism after hip surgery and ...
openaire   +3 more sources

Anticoagulants and Antiplatelets

2020
Knowledge of both anticoagulants and antiplatelets is very important for neuroanesthesiologists. This chapter introduces the anticoagulants and antiplatelets most often encountered during neuroanesthesia practice. Those drugs are listed in Figs. 13.1 and 13.2 based on their classification.
Jibin Mathew, Fenghua Li, Varsha Allampalli, Reza Gorji   +3 more
openaire   +2 more sources

Antiplatelet and antithrombin therapy

Coronary Artery Disease, 1994
The contemporary pharmacologic treatment of acute myocardial infarction (AMI) includes reperfusion via a thrombolytic agent as well as adjunctive therapy with aspirin and heparin (1). Despite the advances made, current management is limited by the fact that infarct-related artery patency is achieved in only 60–80% of patients at 90 min and Thrombolysis
A, Fernández-Ortiz, I K, Jang, V, Fuster   +2 more
openaire   +3 more sources

Pharmacology of Antiplatelet Agents

Current Atherosclerosis Reports, 2013
Pharmacotherapies with agents that inhibit platelet function have proven to be effective in the treatment of acute coronary syndromes, and in the prevention of complications during and after percutaneous coronary intervention. Because of multiple synergetic pathways of platelet activation and their close interplay with coagulation, current treatment ...
Martin G. Gesheff, Christopher J. Franzese, Kevin P. Bliden, Shachi Pandya, Paul A. Gurbel, Udaya S. Tantry, Kiran Kalra, Eli I. Lev   +7 more
openaire   +3 more sources

Antiplatelet therapy – ticagrelor

Hämostaseologie, 2012
SummaryTicagrelor, a cyclopentyltriazolopyrimidine (CPTP), is the representative of a new chemical class of P2Y12 receptor inhibitors that differ from thienopyridines (ticlopidin, clopidogrel, prasugrel) as ticagrelor is not a prodrug requiring active biotransformation by cytochromes in the liver and thus is characterized by a more rapid, more ...
H. A. Katus, E. Giannitsis
openaire   +3 more sources

Exodontia and Antiplatelet Therapy

Journal of Oral and Maxillofacial Surgery, 2008
The fear of excessive bleeding often prompts the physician to stop long-term, low-dose antiplatelet therapy before any surgical procedure. This may put the patient at risk of an adverse thromboembolic event. We undertook an assessment of the incidence of prolonged postoperative bleeding after dental extractions among patients on uninterrupted ...
Nithin A. Shenoy, Balasubramanian Krishnan, Mohan Alexander   +2 more
openaire   +3 more sources

Aspirin as an Antiplatelet Drug

New England Journal of Medicine, 1994
The past 10 years have witnessed major changes in our understanding of the pathophysiologic mechanisms underlying vascular occlusion1,2 and considerable progress in the clinical assessment of aspirin and other antiplatelet agents3–5. The purpose of this review is to describe a rational basis for antithrombotic prophylaxis and treatment with aspirin ...
Alastair J.J. Wood, Carlo Patrono
openaire   +3 more sources

Antiplatelet effect of capsaicin

Thrombosis Research, 1984
Capsaicin was found to be a potent inhibitor of platelet aggregation and release reaction. It inhibited the aggregation of rat platelet induced by collagen and thrombin, but only slightly reduced those of AA and A23187. The IC50 on collagen-induced platelet aggregation was about 85 micrograms/ml.
Jih-Pyang Wang, Che-Ming Teng, Mei-Feng Hsu   +2 more
openaire   +3 more sources